MX341881B - Nanoparticulas de dioxido de silicio y el uso de las mismas para la vacunacion. - Google Patents

Nanoparticulas de dioxido de silicio y el uso de las mismas para la vacunacion.

Info

Publication number
MX341881B
MX341881B MX2011000401A MX2011000401A MX341881B MX 341881 B MX341881 B MX 341881B MX 2011000401 A MX2011000401 A MX 2011000401A MX 2011000401 A MX2011000401 A MX 2011000401A MX 341881 B MX341881 B MX 341881B
Authority
MX
Mexico
Prior art keywords
silicon dioxide
vaccination
dioxide nanoparticles
nanoparticles
relates
Prior art date
Application number
MX2011000401A
Other languages
English (en)
Other versions
MX2011000401A (es
Inventor
Weigandt Markus
Hanefeld Andrea
Kuebelbeck Armin
Larbig Gregor
Original Assignee
Merck Patent Ges Mit Beschrankter Haftung *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschrankter Haftung * filed Critical Merck Patent Ges Mit Beschrankter Haftung *
Publication of MX2011000401A publication Critical patent/MX2011000401A/es
Publication of MX341881B publication Critical patent/MX341881B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

La presente invención se refiere a nanopartículas monodispersas, ultrapequeñas que comprenden dióxido de silicio a la superficie de las cuales se une por lo menos un antígeno. Las nanopartículas se pueden utilizar para la inmunoprofilaxis o inmunoterapia del cáncer. La invención también se refiere a un método para la fijación como objetivo de antígenos en células que presentan antígenos y para la activación del sistema inmune, donde la eficiencia de fijación como objetivo y/o inmunoactivación se establecen por vía de las características de las partículas. La invención también se refiere a un método para la inmunización activa y pasiva de un mamífero.
MX2011000401A 2008-07-15 2009-07-13 Nanoparticulas de dioxido de silicio y el uso de las mismas para la vacunacion. MX341881B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008033175A DE102008033175A1 (de) 2008-07-15 2008-07-15 Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
PCT/EP2009/005078 WO2010006753A2 (de) 2008-07-15 2009-07-13 Siliciumdioxid-nanopartikel und deren verwendung zur vakzinierung

Publications (2)

Publication Number Publication Date
MX2011000401A MX2011000401A (es) 2011-03-15
MX341881B true MX341881B (es) 2016-09-07

Family

ID=41165124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011000401A MX341881B (es) 2008-07-15 2009-07-13 Nanoparticulas de dioxido de silicio y el uso de las mismas para la vacunacion.

Country Status (17)

Country Link
US (4) US8980324B2 (es)
EP (2) EP3241545B1 (es)
JP (3) JP5726075B2 (es)
KR (2) KR101694130B1 (es)
CN (2) CN102099014B (es)
AU (1) AU2009270468B2 (es)
BR (2) BRPI0915788B8 (es)
CA (1) CA2730694C (es)
DE (1) DE102008033175A1 (es)
DK (2) DK2299980T3 (es)
EA (1) EA023047B1 (es)
ES (2) ES2885055T3 (es)
HU (2) HUE054973T2 (es)
MX (1) MX341881B (es)
PT (2) PT2299980T (es)
WO (1) WO2010006753A2 (es)
ZA (1) ZA201101171B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106519588B (zh) 2009-11-09 2019-08-20 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
EP3434642A1 (en) 2010-10-18 2019-01-30 University of Washington through its Center for Commercialization Chromophoric polymer dots
EP2646818A4 (en) * 2010-11-30 2016-09-21 Univ Illinois SILICANANOPARTIKELKONJUGATE
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
CN103012594B (zh) * 2011-09-22 2015-09-02 中国农业科学院兰州兽医研究所 一种运载猪圆环病毒抗原表位蛋白的纳米载体及应用
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
WO2013101902A2 (en) 2011-12-30 2013-07-04 University Of Washington, Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
WO2013116614A1 (en) 2012-02-03 2013-08-08 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
EP2644703A1 (en) * 2012-03-26 2013-10-02 ETH Zurich Molecular code system
GB201205237D0 (en) * 2012-03-26 2012-05-09 Univ Edinburgh Adjuvant
CN105025922B (zh) * 2013-01-31 2018-08-21 波特兰州立大学 包含硅化病毒的免疫原性组合物及其使用方法
CN103175661B (zh) * 2013-03-01 2015-06-24 南京理工大学 一种微纳米生产粉尘泄露源的同位素法定位检测方法
WO2014153051A1 (en) 2013-03-14 2014-09-25 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
WO2016081783A1 (en) * 2014-11-19 2016-05-26 Kiromic, Llc Novel nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies
JP6868862B2 (ja) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
CN105597094A (zh) * 2015-12-31 2016-05-25 河南农业大学 猪传染性胃肠炎病毒纳米硅佐剂灭活疫苗及其制备方法
US10508040B2 (en) * 2016-01-25 2019-12-17 King Abdullah University Of Science And Technology Methods of making silica nanoparticles, propellants, and safety devices
SG10202100422VA (en) 2016-08-10 2021-02-25 Res & Innovation Uk Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy
WO2018035519A1 (en) * 2016-08-19 2018-02-22 Amrita Vishwa Vidyapeetham Compositions and methods for autoimmune disease treatment
DE102017116370A1 (de) * 2017-07-20 2019-01-24 Leibniz-Institut Für Neue Materialien Gemeinnützige Gmbh Siliziumdioxidnanopartikel zur therapeutischen Anwendung
US10952904B2 (en) * 2017-11-28 2021-03-23 International Business Machines Corporation Antimicrobial bandage with nanostructures
WO2019152672A1 (en) * 2018-01-31 2019-08-08 Prolynx Llc Aseptic method and apparatus to prepare sterile formulations of drug-linked hydrogel microspheres
KR102166606B1 (ko) * 2018-10-12 2020-10-16 한국교통대학교산학협력단 대식세포 표적형 나노어셈블리 및 이를 포함하는 항염증 조성물
WO2021092065A1 (en) * 2019-11-04 2021-05-14 Cornell University Ultrasmall nanoparticles and methods of making, using and analyzing same
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN111973741B (zh) * 2020-08-23 2023-01-10 中国医学科学院生物医学工程研究所 pH响应型基于共包载抗原和光敏剂的介孔硅纳米粒的治疗性疫苗的制备方法
CN112641935B (zh) * 2020-10-15 2023-05-23 百葵锐(深圳)生物科技有限公司 一种含颗粒载体的亚单位疫苗及其应用
EP4243602A1 (en) * 2020-11-16 2023-09-20 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114081961B (zh) * 2021-11-10 2024-02-23 中国科学技术大学 复合纳米颗粒、制备方法、应用
CN114377120B (zh) * 2022-01-10 2023-09-22 大连理工大学 一种以病毒样颗粒为模板的二氧化硅疫苗递送系统的构建及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616133A1 (de) * 1985-09-25 1987-11-19 Merck Patent Gmbh Kugelfoermige sio(pfeil abwaerts)2(pfeil abwaerts)-partikel
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
IL109519A (en) * 1994-05-03 1999-03-12 Yeda Res & Dev Vaccines for oral immunization against infecting agents
US6086881A (en) 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
WO2001012221A1 (en) 1999-08-16 2001-02-22 Henceforth Hibernia, Inc. Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
EP1179349B8 (de) * 2000-08-11 2006-06-07 Lohmann Animal Health GmbH & Co. KG W/O-Emulsion-Adjuvanszusammensetzungen für Impfstoffe
CA2453417A1 (en) * 2001-07-10 2003-06-26 North Carolina State University Nanoparticle delivery vehicle
JP2004138522A (ja) * 2002-10-18 2004-05-13 Meneki Seibutsu Kenkyusho:Kk 腫瘍診断剤およびその用途
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
DE102004011110A1 (de) 2004-03-08 2005-09-22 Merck Patent Gmbh Verfahren zur Herstellung monodisperser SiO2-Partikel
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1957045A2 (en) 2005-03-14 2008-08-20 Board of Regents, The University of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
JP4735954B2 (ja) * 2005-06-03 2011-07-27 独立行政法人産業技術総合研究所 抗体産生キャリア
DE102005033954A1 (de) * 2005-07-20 2007-01-25 Switzerland c/o Laris Fiduciara Sca, Ethios Zusammensetzung, die eine liposomale Dispersion von SiO2-Nanopartikeln und ein ß-1,3-verknüpftes Glucanetherderivat umfasst
AU2006288048A1 (en) * 2005-09-08 2007-03-15 Biterials Co., Ltd. Magnetic nanoparticle having fluorescent and preparation method thereof and use thereof
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US8603530B2 (en) * 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US20080171059A1 (en) 2006-08-07 2008-07-17 Shanshan Wu Howland Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
WO2008109366A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
EP2842570B1 (en) * 2007-03-07 2020-05-06 UTI Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
CN100567145C (zh) * 2007-07-19 2009-12-09 东华大学 单分散磁性二氧化硅纳米颗粒的制备方法
EP2376115A4 (en) * 2008-12-11 2013-07-03 Univ Alberta METHODS AND SYSTEMS FOR INDUCING IMMUNOLOGICAL TOLERANCE TO NON-NONE ANTIGENS

Also Published As

Publication number Publication date
BRPI0915788A2 (pt) 2015-11-10
US9808521B2 (en) 2017-11-07
ZA201101171B (en) 2011-10-26
CA2730694C (en) 2017-10-10
CN102099014A (zh) 2011-06-15
JP5726075B2 (ja) 2015-05-27
EA201100190A1 (ru) 2011-08-30
CN105126115A (zh) 2015-12-09
JP2015042694A (ja) 2015-03-05
ES2885055T3 (es) 2021-12-13
JP2017031222A (ja) 2017-02-09
MX2011000401A (es) 2011-03-15
ES2640012T3 (es) 2017-10-31
US20110123620A1 (en) 2011-05-26
HUE054973T2 (hu) 2021-10-28
CA2730694A1 (en) 2010-01-21
JP6479744B2 (ja) 2019-03-06
EP3241545B1 (de) 2021-04-28
US20160303228A1 (en) 2016-10-20
US9433673B2 (en) 2016-09-06
EP2299980B1 (de) 2017-06-14
DE102008033175A1 (de) 2010-01-21
BR122019011790B1 (pt) 2020-12-15
CN105126115B (zh) 2020-11-27
BR122019011790B8 (pt) 2021-07-27
KR20110039351A (ko) 2011-04-15
DK2299980T3 (en) 2017-09-11
AU2009270468A1 (en) 2010-01-21
US10111952B2 (en) 2018-10-30
JP6109805B2 (ja) 2017-04-05
EP3241545A2 (de) 2017-11-08
HUE036309T2 (hu) 2018-06-28
BRPI0915788B8 (pt) 2021-05-25
CN102099014B (zh) 2015-08-26
WO2010006753A3 (de) 2010-04-29
KR101973841B1 (ko) 2019-04-29
DK3241545T3 (da) 2021-07-12
BRPI0915788B1 (pt) 2020-10-20
EA023047B1 (ru) 2016-04-29
KR101694130B1 (ko) 2017-01-09
US8980324B2 (en) 2015-03-17
PT3241545T (pt) 2021-07-30
EP3241545A3 (de) 2017-12-13
PT2299980T (pt) 2017-09-19
US20180071386A1 (en) 2018-03-15
EP2299980A2 (de) 2011-03-30
WO2010006753A2 (de) 2010-01-21
JP2011527996A (ja) 2011-11-10
AU2009270468B2 (en) 2014-08-21
KR20170005169A (ko) 2017-01-11
US20150224189A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
MX341881B (es) Nanoparticulas de dioxido de silicio y el uso de las mismas para la vacunacion.
GB2431582A (en) Dendritic cell vaccines for treating cancer made from embryonic stem cells
WO2012116225A3 (en) Muc1 based glycolipopeptide vaccine with adjuvant
MX2018014602A (es) Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
WO2010104749A8 (en) Antigen presenting cell targeted cancer vaccines
WO2015142671A3 (en) Influenza virus vectors and uses therefor
WO2014165707A3 (en) Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
MY172421A (en) Immunostimulatory oligonucleotides
MX2020011767A (es) Vacunas individualizadas para el cancer.
FR2955773B1 (fr) Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
WO2017210579A8 (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006047515A3 (en) Dendritic cells loaded with heat shocked melanoma cell bodies
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
SG162817A1 (en) Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
WO2009092113A3 (en) Methods and compositions for the delivery of vaccines to disrupted epithelium
EP3792628A3 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
WO2010045573A3 (en) Tumor vaccine
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
TN2009000195A1 (en) Prime boost canine leishmania vaccine
WO2009137577A3 (en) Leishmania vaccine using sand fly salivary immunogen
WO2011140634A3 (en) The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing

Legal Events

Date Code Title Description
FG Grant or registration